We demonstrate that combined targeting of the T cell costimulatory receptor CD137 and coinhibitory receptor PD-1 enhances the therapeutic efficacy of SBRT in a mouse model of human BRAFV600-driven melanoma. The gene discussed is TNFRSF9; the disease is melanoma.